Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-13 11:45:08 UTC |
---|
Update Date | 2023-02-21 17:29:00 UTC |
---|
HMDB ID | HMDB0041872 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Detomidine |
---|
Description | A profound lethargy and characteristic lowering of the head with reduced sensitivity to environmental stimuli (sound, pain, etc.) are seen with detomidine. A short period of reduced coordination is characteristically followed by immobility and a firm stance with front legs spread. Following administration there is an initial increase in blood pressure, followed by bradycardia and second degree atrioventricular block (this is not pathologic in horses). The horse commonly sweats to excess, especially on the flanks and neck. Other side effects reported include pilo erection (hair standing erect), ataxia, salivation, slight muscle tremors, and (rarely) penile prolapse. An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem]; As detomidine is an arrhythmogenic agent, extreme care should be exercised in horses with cardiac disease, and in the concurrent administration of other arrhythmogenics. The concurrent use of potentiated sulfonamide antibiotics is considered particularly dangerous. Detomidine is a poor premedication when using Ketamine as an anesthetic in horses. Detomidine is a sedative with analgesic properties. 2-adrenergic agonists produce dose-dependent sedative and analgesic effects, mediatated by activation of catecholamine receptors, thus inducing a negative feedback response, reducing production of excitatory neurotransmitters. Due to inhibition of the sympathetic nervous system, detomidine also has cardiac and respiratory effects and an antidiuretic action. Detomidine is an imidazole derivative and I-adrenergic agonist, used as a large animal sedative, primarily used in horses. It is usually available as the salt detomidine hydrochloride. It is a prescription medication available to veterinarians sold under the trade name Dormosedan. |
---|
Structure | CC1=C(C)C(CC2=CN=CN2)=CC=C1 InChI=1S/C12H14N2/c1-9-4-3-5-11(10(9)2)6-12-7-13-8-14-12/h3-5,7-8H,6H2,1-2H3,(H,13,14) |
---|
Synonyms | Value | Source |
---|
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole | HMDB | 4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole | HMDB | Dexdor (T) | HMDB | Dexmedetomidina | HMDB | Dexmedetomidine | HMDB | Dexmedetomidinum | HMDB | Medetomidine | HMDB | MPV 1440 | HMDB | Detomidine hydrochloride | HMDB | Detomidine monohydrochloride | HMDB |
|
---|
Chemical Formula | C12H14N2 |
---|
Average Molecular Weight | 186.253 |
---|
Monoisotopic Molecular Weight | 186.115698458 |
---|
IUPAC Name | 5-[(2,3-dimethylphenyl)methyl]-1H-imidazole |
---|
Traditional Name | detomidine |
---|
CAS Registry Number | 76631-46-4 |
---|
SMILES | CC1=C(C)C(CC2=CN=CN2)=CC=C1 |
---|
InChI Identifier | InChI=1S/C12H14N2/c1-9-4-3-5-11(10(9)2)6-12-7-13-8-14-12/h3-5,7-8H,6H2,1-2H3,(H,13,14) |
---|
InChI Key | RHDJRPPFURBGLQ-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as o-xylenes. These are aromatic compounds that contain a o-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 2-positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Xylenes |
---|
Direct Parent | o-Xylenes |
---|
Alternative Parents | |
---|
Substituents | - O-xylene
- Heteroaromatic compound
- Imidazole
- Azole
- Azacycle
- Organoheterocyclic compound
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 146.8 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Detomidine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0670-2900000000-8ba524c959b883c9ecda | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Detomidine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 10V, Positive-QTOF | splash10-000i-0900000000-0f8f38c05df0f8c98d31 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 20V, Positive-QTOF | splash10-000i-0900000000-39f1a801ba925643f510 | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 40V, Positive-QTOF | splash10-05mo-4900000000-657907c5462aa1a1cadc | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 10V, Negative-QTOF | splash10-000i-0900000000-de51e91769533f1baf23 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 20V, Negative-QTOF | splash10-000i-1900000000-01409404871e24d18c79 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 40V, Negative-QTOF | splash10-014l-5900000000-17a9566856eeb1bf13a5 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 10V, Positive-QTOF | splash10-000i-0900000000-f6ccc8b16f0705551f96 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 20V, Positive-QTOF | splash10-000i-2900000000-67a15cc632a6d93d907a | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 40V, Positive-QTOF | splash10-0f96-9600000000-33da807a81d06a9565ad | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 10V, Negative-QTOF | splash10-000i-0900000000-518da453fd1641c12549 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 20V, Negative-QTOF | splash10-0aor-4900000000-66acc658a98a9d0d1248 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Detomidine 40V, Negative-QTOF | splash10-0693-3900000000-43595eaaac431de8ef3c | 2021-09-22 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-04 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-04 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-04 | FELIX lab | View Spectrum |
|
---|